Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN (=< 5 x ULN for patients with documented liver metastases)
Obtained within 28 days prior randomization: aspartate aminotransferase (AST) and alanine aminotransferase (ALT) must be =< 3 x ULN for the lab with the following exception: for patients with documented liver metastases, AST and ALT must be =< 5 x ULN
Aspartate aminotransferase (AST) ? 2.5 × ULN without liver metastases; must be ? 5 × ULN with liver metastases
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2.5 × ULN or ? 5 × ULN for patients with liver metastases
Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5 x ULN in patients with liver metastasis) (=< 28 days prior to registration)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x ULN (or =< 5.0 x ULN if liver metastases are present)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN (unless elevated transaminases are felt to be directly related to metastatic disease involving the liver, in which case AST and ALT must be =< 5 x ULN) must be met within 28 days of C1D1
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 3 x the institutional ULN\r\n* Note that physician attestation of patient having no known history of liver disease can take the place of bilirubin and AST/ALT labs
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 3 x ULN; if liver metastases are present, then ? 5 x ULN is allowed.
Serum transaminases (alanine aminotransferase [ALT] and aspartate aminotransferase [AST]) =< 2.5 x ULN in the absence of liver metastases and =< 5 x ULN in case of liver metastases
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN; for patients with hepatic metastases, ALT and AST =< 5 x ULN
Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) < 2.5 x ULN; if liver metastases, ALT/AST =< 5.0 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5 x ULN in patients with liver metastases)
Alanine aminotransferase or aspartate aminotransferase < 2.5 x the ULN or < 5 x the ULN if secondary to liver metastasis
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2.5 x ULN (or =< 5 x ULN for subjects with liver metastasis)
Alanine aminotransferase (ALT)/aspartate aminotransferase (AST), should be less than or equal to 1.5 x ULN (CTCAE v4.0, grade 1); for patients with liver metastases, ALT/AST should be less than or equal to 2.5 x ULN (CTCAE v4.0 grade 1)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2.5 x ULN; AST and ALT ? 5 × ULN for patients with liver metastasis
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN; if the patient has liver metastases, ALT and AST must be =< 5 x ULN.
Within 10 (except as noted) days of planned treatment initiation: Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x institutional ULN OR =< 5 x ULN for patients with known liver metastases
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 x ULN or < 5 x ULN if liver metastases
PHASE II INCLUSION CRITERIA: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 x ULN or < 5 x ULN if liver metastases
Aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase =< 2.5 x ULN, or =< 5 x ULN in subjects with liver metastases within 28 days of treatment initiation and must be independent of hematopoietic growth factor support
In the absence of liver metastases, alanine aminotransferase (AST) and aspartate aminotransferase (ALT) should be below 3.0 × ULN. If the participant has liver metastases, ALT and AST should be below 5.0 × ULN.
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x ULN or < 5 x the ULN if liver metastasis performed within 30 days prior to the date of registration
alanine aminotransferase /aspartate aminotransferase (ALT/AST) ?2.5 x ULN without, and ? 5 x ULN with hepatic metastases
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN or =< 5 x ULN for patients with liver metastases within 8 weeks of pre-registration
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN or =< 5 x ULN if liver metastases
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 ULN or =< 5 x ULN if liver mets are present
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ?2.5 × institutional ULN OR ?5 × institutional ULN for participants with liver metastases
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) at =< 2.5 x ULN (in case of liver metastasis AST/ALT at =< 5.0 x ULN)
Alanine aminotransferase (AST) and aspartate aminotransferase (ALT) =< 2.5 x ULN (or =< 5 x ULN if liver metastases are present)
Patients are eligible with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) up to 3 x ULN; (up to 5 x ULN if liver metastases present)
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x ULN for patients without liver metastasis, =< 5 times for patients with liver metastases
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 X ULN (or < 5 x ULN with liver metastases)
Aspartate aminotransferase (AST) and alanine-aminotransferase (ALT) levels =< 2.5 x ULN or, for patients with documented metastatic disease to the liver, AST and ALT levels =< 5 x ULN
Aspartate aminotransferase (AST) =< 2.5 x ULN or =< 5 x ULN if judged by the investigator to be related to liver metastases
Alanine aminotransferase and aspartate aminotransferase =< 2.5 x ULN, (=< 5.0 x ULN with documented liver metastases) within 14 days prior to first dose of protocol-indicated treatment.
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ?3x the ULN (?5x the ULN for subjects with liver metastases)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ? 2.5 x ULN, unless liver metastases are present, then values must be ? 5 x ULN)
Within 28 days prior to registration: Aspartate aminotransferase (AST) =< 2.5 x ULN (or =< 5 x ULN if liver metastases)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2.5 times the ULN range of each institution. With the following exceptions: subjects with documented liver metastases; AST and ALT < 5 x ULN.
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x institutional ULN OR =< 5 x ULN for subjects with liver metastases
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN, unless liver metastases are present, then values must be =< 3 x ULN
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ? 3 x institutional ULN (? 5 x ULN in the presence of liver metastases)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 3 x ULN (or ? 5.0 x ULN if hepatic metastases are present)
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2.5 x ULN OR =< 4 x ULN for subjects with liver metastases
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN, unless associated with hepatobiliary metastases, in that case =< 5 x ULN
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2 x ULN without liver metastasis; =< 5 x ULN with liver metastasis
Within 28 days prior to enrollment: Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2.5 X ULN OR =< 5 X ULN for subjects with liver metastases
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN except for subjects with liver mets for whom ALT and AST should be =< 5 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN (results within 7 days before study drug administration), =< 5 x ULN for patients with liver metastases
Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 3 x ULN (or > 5 x ULN for patients with concurrent liver metastasis)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels ? 2.5 × ULN or AST and ALT levels ? 5 x ULN for subjects with documented metastatic disease to the liver; patient with history of unconjugated hyperbilirubinemia with otherwise acceptable liver enzyme levels (as per above criteria) may have higher bilirubin levels
Performed within 14 days of treatment initiation: Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2.5 X ULN OR =< 5 X ULN for subjects with liver metastases
Obtained within 14 days prior to the first study treatment (cycle 1, day 1): aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN with the following exception: 1) patients with documented liver metastases: AST and/or ALT =< 5 x ULN
Within 14 days of the first study treatment: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels =< 2.5 x ULN or AST and ALT levels =< 5 x ULN (for subjects with documented metastatic disease to the liver)
alanine aminotransferase (ALT, SGPT) and aspartate aminotransferase (AST, SGOT) ? 2.5 x ULN (? 5 x ULN if liver metastases are present);
AST (aspartate aminotransferase) =< 2 x ULN\r\n* NOTE: ALT and/or AST may be =< 5 x ULN if due to liver metastases. If ALT or AST is > 2 and =< 5 x ULN in patients with liver metastases
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x institutional ULN (=< 5 x institutional ULN if there is liver metastasis)
Determined within 3 weeks of treatment initiation: Aspartate aminotransferase (AST) =< 2.5 x ULN OR =< 5 x ULN for subjects with liver metastases
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 x ULN (> 5 x ULN if liver metastases are present)
Aspartate aminotransferase (AST), level =< 2.5 x ULN, and an alanine aminotransferase (ALT) level =< 2.5 x ULN or, for subjects with documented metastatic disease to the liver, AST and ALT levels =< 5 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN unless liver metastases are present, in which case it must be =< 5 x ULN.
Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ? 2.5 x ULN or ? 5x ULN if known liver metastases
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN if no demonstrable liver metastases or =< 5 x ULN in the presence of liver metastases
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN (ALT and AST =< 5 x ULN is acceptable if liver metastases are present)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN or =< 5 x ULN if liver metastases are present
In absence of liver metastases, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) should be below 2.5 × ULN. If the patient has liver metastases, ALT and AST should be < 5 × ULN.
Alanine aminotransferase (ALT) =< 1.5 x ULN, aspartate aminotransferase (AST) =< 1.5 x ULN); ALT and AST =< 5 x ULN if documented liver metastases
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT):\r\n* > 2.5 x ULN\r\n* > 5 x ULN, if liver metastasis present
Aspartate aminotransaminase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN OR =< 5.0 x ULN if liver metastases present
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN; for subjects hepatic metastases, ALT and AST =< 5 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels =< 2.5 x ULN; if liver metastases are present, then AST and ALT =< 5 x ULN
Transaminases (aspartate aminotransferase-AST and alanine aminotransferase ALT) =< 2.5 x ULN (=< 5 x ULN if liver metastases are present)
Aspartate aminotransferase and/or alanine aminotransferase =< 3 x ULN (=< 5 x ULN if liver metastases are present) within 30 days prior to C1D1
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN (or =< 4.0 x ULN if hepatic metastases are present)
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) > 2.5 x ULN; for patients with liver metastases: AST/ALT > 5 x ULN
Aspartate aminotransferase (AST) =< 2.5 x ULN; =< 5 x ULN if liver metastases are present
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) > 10 x ULN, unless related to ALL liver infiltration
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN (or =< 5.0 x ULN if hepatic metastases are present)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN or =< 5 x ULN for subjects with liver metastases
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 5 x ULN, except patients who are assigned to receive docetaxel must have liver function tests (serum transaminases, bilirubin) that are within 1.5 x the ULN
Must be met within 28 days of C1D1: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x UNL (unless elevated transaminases are felt to be directly related to metastatic disease involving the liver, in which case AST and ALT must be =< 5 x ULN)
Alanine transaminase (ALT) and aspartate aminotransferase (AST) < 1.5 x ULN (< 5 x ULN if patient has liver metastasis)
aspartate aminotransferase (AST) and alanine aminotransferase (ALT) must be less than or equal to 1.5 x ULN for the lab or less than or equal to 5 x ULN if liver metastasis.
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN or =< 5 x ULN if liver metastases are present
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x ULN; AST/ALT =< 5 x ULN if liver metastasis is present (to be performed within 7 days prior to start of study treatment)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN or =< 5 x ULN if liver metastases are present
Within 14 days of enrollment: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) > 2.5 x ULN, unless there are liver metastases in which case AST and ALT or > 5 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN (in the case of liver metastases, =< 5 x ULN)
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x ULN for patients without liver metastasis, =< 5 x ULN for liver metastases
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 × ULN or < 5 × ULN in the setting of liver metastases
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5 x ULN in patients with liver metastases)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2.5 x ULN without liver metastases (or ? 5 x ULN if liver metastases are present)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ? 2.5 x ULN (? 5 x ULN for subjects with liver metastases)
Aspartate aminotransferase (AST), alanine aminotransferase (ALT) < 2.5 x institutional ULN or =< 5 x the institution ULN in the presence of known liver metastases
Aspartate aminotransferase (AST) =< 2.5 x ULN; note: if the patient has liver metastases present, then =< 5 x ULN
Hepatic: bilirubin <1.5 X ULN; alanine aminotransferase (ALT) or aspartate aminotransferase (AST) < 2.5 X ULN. Patients with known liver metastases or liver neoplasms: alanine aminotransferase (ALT) or aspartate aminotransferase (AST) < 5.0 X ULN
Within 14 days prior to randomization: Aspartate aminotransferase (AST) and alanine aminotransaminase (ALT) must be =< 2.5 x ULN for the lab or =< 5 x ULN for patients with liver metastases.
Within 14 days of first dose of study drug: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN; if liver metastases, then =< 5 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) must be =< 2.5 x ULN, except if the elevations are due to hepatic metastases, in which case ALT and AST must be =< 5 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN OR < 5 x ULN if patient has liver metastasis
Within 14 days prior to first dose of study drug treatment: Aspartate aminotransferase (AST), alanine aminotransferase (ALT) =< 3 x ULN with the following exceptions:\r\n* Patients with documented liver metastases: AST and/or ALT =< 5 x ULN
Aspartate aminotransferase (AST) ? 3 x ULN OR ? 5 x ULN (if liver metastases present)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN unless liver metastases are present, in which case it must be =< 5x ULN.
Aspartate aminotransferase (AST), alanine aminotransferase (ALT) or alkaline phosphatase < 2.5 x ULN OR =< 5 x ULN for subjects with liver metastases
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x ULN, obtained within 14 days prior to the first study treatment (cycle 1, day 1) with the following exception:\r\n* Patients with liver metastases may enroll with AST and ALT =< 5 x ULN
To be performed within 28 days prior to day 1 of protocol therapy: Aspartate aminotransferase (AST) =< 2.5 x ULN if no liver metastases or =< 5 x ULN if liver metastases
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN (=< 5 x ULN for patients with documented liver metastases)
In absence of liver metastases, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN; if the patient has liver metastases, ALT and AST =< 5.0 x institutional ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN; in the case of known (radiological and/or biopsy documented) liver metastasis, the AST/ALT =< 5 times ULN is acceptable
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 2 x ULN unless related to metastatic breast cancer to the liver (in which case AST/ALT < 5 x ULN is allowed)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2 x ULN (=< 5 x ULN for patients with documented liver metastases)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5 x ULN in patients with liver metastases)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) >= 3 x ULN (with or without liver metastasis [mets])
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x ULN; in the setting of metastatic disease to the liver, AST/ALT may be =< 5 x ULN
Aspartate and alanine aminotransferase (AST & ALT) ?3.0 x ULN or ?5.0 x ULN if subject has liver metastasis;
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 times ULN (or 5.0 x ULN in the setting of liver metastases)
Aspartate aminotransferase (AST) =< 2.5 x ULN, or =< 5 x ULN if liver metastases are present
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 1.5 ULN if without liver metastases
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x ULN for patients without liver metastases and =< 5 x ULN for patients with liver metastases
aspartate aminotransferase, alanine aminotransferase ? 2.5 X ULN, or ? 5.0 X ULN (if liver metastasis present)
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x ULN (=< 5 x ULN in the presence of liver metastases)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN OR =< 5.0 x ULN if liver metastases present (within 14 days prior to day 1 of protocol therapy)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN, unless liver metastases are present, then values must be =< 3 x ULN)
Prior to cyclophosphamide and T cell infusions: aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 5 x ULN (since all patients will have liver metastasis)
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 1.5 X ULN; < 3 X ULN if known hepatic metastases =< 7 days prior to randomization
Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) up to 2.5 x ULN if no liver metastases or ALT or AST up to 5 x ULN if liver metastases present
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x ULN; for subjects with documented metastatic disease to the liver, AST and ALT levels =< 5 x ULN
Within 72 h of initiating study treatment: Aspartate aminotransferase (AST) =< 2.5 x ULN OR < 5 x ULN for liver metastases (mets)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< ULN (or =< 3 x ULN if liver involved with disease
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN, unless associated with hepatobiliary metastases, in that case =< 5 x ULN
Aspartate aminotransferase (AST) =< 3.0 X ULN (=< 5.0 X ULN if liver metastases are present)
Alanine aminotransferase (ALT), and aspartate aminotransferase (AST) =< 2.5 x ULN (for patients with liver metastases, =< 5 x ULN)
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2.5 X ULN OR =< 5 X ULN for subjects with liver metastases
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x ULN for patients without liver metastasis, =< 5 times for liver metastases
The aspartate aminotransferase (AST) and alanine aminotransferase (ALT) must not be more than 2.5 x ULN within 72 hours prior to enrollment, or greater than 5.0 X ULN if in the Investigator’s judgment it is related to liver metastases; AST and ALT may be up to 5 x ULN within 72 hours prior to enrollment in participants with hepatic metastases
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ? 2.5 x ULN unless associated with hepatic metastases, then ALT and AST ? 5 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels =< 2.5 x ULN or AST and ALT levels =< 5 x ULN (for subjects with documented metastatic disease to the liver)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN or =< 5 x ULN if caused by liver metastasis
Aspartate aminotransferase (AST) =< 2.5 x ULN, or =< 5 x ULN if liver metastases are present
No liver metastases: aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN; liver metastases: AST and ALT =< 5 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN, or =< 5 x institutional ULN in subjects with liver metastasis
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5 x ULN in patients with liver metastases)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN (=< 5 x ULN if liver metastases are present)
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >= 2.5 x ULN (for patients with known liver metastasis, AST or ALT =< 3 x ULN is allowed) at the screening visit
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 1.5 x ULN (or < 5 x ULN if known liver metastases)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) > 2.5 x ULN (AST and ALT > 5 x ULN for subjects with liver metastasis)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN in the absence of liver metastases; AST and ALT =< 5 x ULN in the presence of liver metastases
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5 x ULN in patients with liver metastases)
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x ULN for patients without liver metastasis
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN for institution or =< 5 x ULN for institution if clearly attributable to liver metastases
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT): ~ 2.5 x ULN for subjects without liver metastasis ~ 5 times for liver metastases
For subjects without liver metastases: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2.5 x ULN (=< 5 x ULN if liver metastases are present)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST)  =< 2.5 x ULN or =< 5.0 x ULN for subjects with liver metastases
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 1.5 x ULN (or =< 3 x ULN if liver involved with disease
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN (=< 5.0 ULN in the presence of liver metastases)
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x ULN (unless liver metastases, who can have AST/ALT =< 5 x ULN)
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 3 x ULN (patients with documented liver metastases: AST and/or ALT =< 5 x ULN)
Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 1.5 x ULN in pts without liver metastasis; for pts with liver metastasis: ALT or AST > 2.5 x ULN
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT): =< 2.5 x ULN for subjects without liver metastasis; =< 5 times for liver metastases
Alanine aminotransferase (AST) or aspartate aminotransferase (ALT) > 3.0 x ULN (or < 5.0 x ULN if liver metastases are present)
Aspartate aminotransferase (AST) / alanine aminotransferase (ALT) < 3 x ULN (< 5 x ULN for patients with documented liver metastases)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2.5 x ULN, or AST and ALT ? 5 x ULN if liver function abnormalities are due to underlying malignancy
Serum transaminases (alanine aminotransferase [ALT] and aspartate aminotransferase [AST]) ? 2.5 x ULN in the absence of liver metastases or =< 5 ULN in case of liver metastases)
Serum alanine aminotransferase/serum aspartate aminotransferase (ALT/AST) < 2.5 x ULN; for patients with liver metastases, ALT/AST < 5 x ULN is acceptable
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x ULN (for subjects with liver metastases AST/ALT may be =< 5 x ULN)
Aspartate aminotransferase (AST) and alkaline phosphatase =< 2.5 x ULN (CTCAE v4.03 grade 1; AST and alanine aminotransferase [ALT] =< 3 x ULN [or =< 5.0 x ULN if hepatic metastases are present])
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x institutional ULN unless metastatic to liver in which case AST and ALT should be < 5 x institutional ULN
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x ULN; for subjects with documented liver metastases, the AST/ALT may be =< 5 x ULN
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ? 3 x ULN (or < 5 x ULN in subjects with liver metastases or hepatocellular carcinoma).
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN or =< 5 x ULN if liver metastases are present
Alanine aminotransferase and AST ? 2.5 × ULN; for subjects with hepatic metastases, ALT and AST ? 5 × ULN
Alanine aminotransferase and aspartate aminotransferase =< 2.5 x ULN or =< 5.0 x ULN in case of documented hepatic metastasis
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 1.5 x ULN (ALT and AST =< 2.5 x ULN is acceptable if there is liver metastasis)
Hepatic: Direct bilirubin ?1.5 X ULN; alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ? 2.5 X ULN. For patients with known liver metastases or liver neoplasms, then ALT or AST ? 5.0 X ULN is allowed
Aspartate aminotransferase (AST)/Alanine transferase (ALT) (SGOT/SGPT) < 2.5 x ULN for the reference laboratory or < 5 x ULN in the presence of liver metastases
Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) ?2.5 X ULN (?5 x ULN in patients with liver metastases)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3.0 x ULN (with or without liver metastases)
Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ? 2.5 x ULN or ? 5x ULN if known liver metastases
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 3 x ULN or < 5 x ULN if known liver metastases
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2.5 × ULN unless liver metastases are present, in which case they must be ? 5 × ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2.5 × ULN unless liver metastases are present, in which case they must be ? 5× ULN
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) less than or equal to 2.5 x ULN unless liver metastasis is present then up to 5 X ULN permitted
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN or =< 5 x ULN if liver metastases are present
Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) < 5 X ULN in case of liver metastases
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x ULN (< 5 x ULN if liver metastases are present)
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x ULN for patients without liver metastasis, =< 5 times for liver metastases
Aspartate aminotransferase (AST) =< 1.5 x ULN; alanine aminotransferase (ALT) and AST =< 3 x ULN is acceptable if there is liver metastasis
Have significant hepatic dysfunction (aspartate aminotransferase [AST]/alanine aminotransferase [ALT] >= 2 x ULN or reported liver disease)
Aspartate aminotransferase (AST) =< 2.5 x ULN OR < 5 x ULN for subjects with liver metastases, obtained within 14 days prior to C11-AMT PET scan
Abnormal liver functions consisting of any of the following:\r\n* Serum bilirubin >= 1.5 x ULN (except for patients with documented Gilbert’s disease)\r\n* Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >= 2.5 x ULN, (for patients with known liver metastasis, AST or ALT =< 5 x ULN is allowed)